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Background: The Bipolar Comprehensive Outcomes Study (BCOS) is a 2-year, prospective, non-interventional,
observational study designed to explore the clinical and functional outcomes associated with ‘real-world’ treatment
of participants with bipolar I or schizoaffective disorder. All participants received treatment as usual. There was no
study medication.
Methods: Participants prescribed either conventional mood stabilizers (CMS; n = 155) alone, or olanzapine with,
or without, CMS (olanzapine ± CMS; n = 84) were assessed every 3 months using several measures, including the
Young Mania Rating Scale, 21-item Hamilton Depression Rating Scale, Clinical Global Impressions Scale – Bipolar
Version, and the EuroQol Instrument. This paper reports 24-month longitudinal clinical, pharmacological, functional,
and socioeconomic data.
Results: On average, participants were 42 (range 18 to 79) years of age, 58% were female, and 73% had a diagnosis
of bipolar I. Polypharmacy was the usual approach to pharmacological treatment; participants took a median of 5
different psychotropic medications over the course of the study, and spent a median proportion of time of 100%
of the study on mood stabilizers, 90% on antipsychotics, 9% on antidepressants, and 5% on benzodiazepines/
hypnotics. By 24 months, the majority of participants had achieved both symptomatic and syndromal remission of
both mania and depression. Symptomatic relapse rates were similar for both the CMS alone (65%) and the
olanzapine ± CMS (61%) cohorts.
Conclusions: Participants with bipolar I or schizoaffective disorder in this study were receiving complex medication
treatments that were often discordant with recommendations made in contemporary major treatment guidelines.
The majority of study participants demonstrated some clinical and functional improvements, but not all achieved
remission of symptoms or syndrome.* Correspondence: jayashri.kulkarni@monash.edu
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Bipolar disorder (BD) is a complex and severe mental
illness, with a fluctuating course, characterized by acute,
affective episodes with full or partial inter-episode remis-
sions. Adding to the complexity of BD is the “mixed”
affective syndrome, in which the person experiences
both depressive and manic symptoms simultaneously
[1]. The lifetime prevalence of BD I (manic, mixed or
depressed) and BD II (hypomanic, depressed) is esti-
mated as 2.1% of the US population, however, if one
considers sub-threshold cases, the lifetime prevalence
may be as high as 4.5% [2]. Similar figures were reported
by a recent Australian-based study in which the preva-
lence of BD was estimated between 2.5% and 2.9% [3,4].
The global burden of BD is significant as it represents
the sixth leading cause of years lived with disability [5].
Individuals with BD often also suffer from comorbid
psychological and medical issues and are more likely to
commit suicide [6]. A recent US-based survey found
that many respondents with BD also had histories of
anxiety (75%), impulse-control (63%) and/or substance
use (42%) disorders; with 70% of these respondents
experiencing ≥3 disorders [2].
Due to the varying mood-states and different expressions
of the illness, management of BD is complicated. For
decades, lithium was considered the cornerstone of phar-
macologic treatment for BD [7] and remains a first line
treatment in most major guidelines [8,9]. However, an
increasingly diverse range of pharmacological agents (i.e.,
anticonvulsants, antidepressants and antipsychotics) has
found a place in the treatment of BD at different stages of
the illness [10-15]. Surveys of prescribed medicines used
for the treatment of BD have consistently described com-
plex treatment regimens, with polypharmacy being the
norm rather than the exception [16].
Several large observational studies of patients with BD
and schizoaffective disorder (SAD) have been conducted
and subsequently published [17-24]. Among them, the
Bipolar Comprehensive Outcomes Study (BCOS) is a
2-year, prospective, non-interventional, observational
study designed with the purpose of improving the
understanding of treatment and outcomes of patients
diagnosed with BD I or SAD [21-24]. The rationale for
studying these two patient populations concomitantly is
that both SAD and BD share common features as well
as treatment approaches [25,26]. The BCOS was designed
to provide a comprehensive assessment of outcomes.
Several key benefits of the BCOS are: a) it is the first
prospective observational study conducted in Australia
assessing this patient population; b) detailed information
on clinical status and medications taken (including
validated sources of medications prescribed) were col-
lected; and c) the study design allowed for information
from many data sources to be integrated (i.e., case reportform data, national health insurance claims, and hospital
and community data).
The observational design was chosen for the BCOS to
complement information available from other study
designs, such as randomized controlled trials (RCTs).
While RCTs have higher internal validity, observational
studies offer several advantages over RCTs including: a)
lower cost; b) increased timeliness; c) fewer inclusion
and exclusion criteria, thus providing an opportunity to
study a more diverse patient population over longer peri-
ods of time in a naturalistic setting; and most importantly,
d) the ability to identify risk factors and prognostic indica-
tors in situations which would be impossible or unethical
for RCTs [25,27-30]. With a complex condition like BD, it
was hoped that the observational design would help to
achieve the study objectives.
The broad objective of BCOS was to better understand
the long-term clinical, functional, social and economic
outcomes achieved by participants being treated for BD
I or SAD. As part of this objective, we aimed to evaluate
current clinical practices, including pharmacological
treatment. Specifically, we were interested in examining
the 2-year outcomes for participants following treatment
with either conventional mood stabilizers (CMS) alone,
or olanzapine with, or without, CMS (olanzapine ± CMS).
Methods
Study design
The BCOS was a 2-year, prospective, non-interventional,
observational study of outpatients prescribed CMS with
or without olanzapine for the treatment of BD I or SAD
(study code F1D-AY-B004). All participants provided
informed consent to participate in the study, which was
conducted in accordance with Australian ethics and
privacy laws. Detailed information about the study
design, patient populations and methodology has been
previously published [22]. In short, the BCOS was con-
ducted at two sites in Victoria, Australia: the Monash
Alfred Psychiatry Research Centre at the Alfred and
Monash University in Melbourne, and the Barwon
Psychiatric Research Unit in Geelong. This study in-
cluded consenting males and females at least 18 years of
age, with a primary diagnosis of BD I (manic, mixed, or
depressed episode) or SAD as defined by the Diagnostic
and Statistical Manual of Mental Disorders, Fourth
Edition Text Revision (DSM-IV-TR) [31], and their
diagnosis was confirmed by the Mini-International
Neuropsychiatric Review (MINI) Version 5 [32]. In
addition, participants had to be prescribed at least one
of the following CMS (lithium carbonate, sodium val-
proate, or carbamazepine) or olanzapine as a mood
stabilizer, or a combination of CMS plus olanzapine,
actively participated in the interview process, and were
willing and able to complete the self-administered
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of participants, exclusion criteria were minimal, only
those participants: with a DSM-IV-TR diagnosis of
schizophrenia, organic psychosis or dementia; involved
in a controlled clinical trial 30 days prior to the study or
at any time during the study; who did not meet all of the
inclusion criteria; were considered ineligible. Trained
evaluators assessed participants on 9 separate occasions
– at study entry, and every 3 months up to 24 months.
Data were obtained from participant interviews, patient
medical records, and electronic administrative health
care records, and were incorporated into a running
record. Information collected included quality of life
(both subjective and objective measures), use of con-
comitant medications, stability of treatment, medication
adherence (patient self-reported), employment status,
and any lost productivity due to illness. This study was
not designed to assess safety; all adverse events were
reported to the Adverse Drug Reactions Advisory Com-
mittee in accordance with Australian safety requirements.
Treatment
Since this was an observational study, participants were
not randomized to treatment, but instead, were main-
tained on their prior medication regimen. All treatment
decisions were made by the participant’s primary treat-
ing clinicians, independent of the study. Participants
were recruited (from September 2003 to November
2005) into one of two cohorts: a) those who were receiv-
ing at least one of the listed CMS, excluding olanzapine
(i.e., CMS alone); or b) those receiving, olanzapine as a
mood stabilizer alone, or in combination, with at least
one of the listed CMS (i.e., olanzapine ± CMS), at study
entry. Selection of the pre-specified treatments included
in this study was based on the approved indication and
frequency of use of each of these treatments in Australia
at that time. Participants with BD I were not recruited
into the olanzapine ± CMS cohort until the Therapeutic
Goods Administration granted approval for the use of
olanzapine for preventing the recurrence of manic,
mixed, or depressive episodes in BD I in October 2003.
Measures and definitions
Clinician and study participant self-rated measures were
used to capture a range of clinical, social and functional
outcomes associated with treatment throughout the
2-year observation period. The clinical status of each
participant was assessed using the following scales: a)
Clinical Global Impressions-Bipolar Version Severity of
Illness scale (CGI-BP) [33]; b) Young Mania Rating Scale
(YMRS) [34]; and c) 21-item Hamilton Depression
Rating scale (HAMD21) [35].
Symptomatic remission from a manic state was
defined as a YMRS total score of ≤12 [36] and HAMD21total score of ≤8; from a depressive state, remission
was defined as a HAMD21 total score of ≤8 (based on
the consensus definition proposed by the International
Society for Bipolar Disorders task force, assuming the
equivalence of HAMD21 ≤ 8 and HAMD17 < 5 or <7
[37]). Relapse rates were only assessed in those partici-
pants that achieved symptomatic remission as defined
previously. Symptomatic relapse to a manic state was
defined as a YMRS total score of ≥15 in only those parti-
cipants who met the criteria for symptomatic remission
of mania. Relapse to a depressed state was defined as a
HAMD21 total score of ≥15 in only those participants
who met the criteria for symptomatic remission of
depression. A psychiatric hospital admission also defined
a symptomatic relapse in those participants who previ-
ously established symptomatic remission.
Definitions of syndromal remission were modified
from those used in the McLean first-episode psychosis
project [38]. Syndromal remission from a manic state
was defined as all DSM-IV-TR ‘A’ and ‘B’ criteria for
current manic episode being no worse than mild (≤3 on
a 1 to 7 scale), and no more than two ‘B’ criteria rated as
mild (=3 on a 1 to 7 scale). Syndromal remission from a
depressive state was defined as all DSM-IV-TR ‘A’ criteria
for current major depressive episode no worse than mild
(≤3 on a 1 to 7 scale), and no more than three ‘A’ criteria
rated as mild (=3 on a 1 to 7 scale). Relapse rates were
only assessed in those participants who achieved syndro-
mal remission as defined previously. Syndromal relapse
to a manic state was defined as meeting DSM-IV-TR
criteria for a current manic episode in only those partici-
pants who previously fulfilled the criteria for syndromal
remission of mania. Relapse to a depressed state was
defined as meeting DSM-IV-TR criteria for a current
depressive episode in only those participants who first
met the criteria for syndromal remission for depression.
The EuroQol instrument (EQ-5D) [39] and 36-item
Short-Form Health Survey (SF-36) [40] were used to
capture self-reported health-related quality of life. The
social functioning of participants was evaluated using
the Streamlined Longitudinal Interview Clinical Evalu-
ation from the Longitudinal Interval Follow-up Evaluation
(SLICE/LIFE) [41], and the Diagnostic Interview for
Psychosis (DIP) [42] was used to rate impairment in work,
housework, and study. Medical history and sociodemo-
graphic information were collected at study entry; key
items such as employment status and suicidality were
collected throughout the study. Information about phar-
macological treatments taken, including dosage, start and
stop dates, previous medication history, stability of treat-
ment and adherence (patient self-reported) was collected
at each visit for all mood stabilizers, antipsychotics, and
antidepressants. Concomitant use of psychotropic medica-
tions was also captured.
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In order to fully explore the relationship between treat-
ment and outcomes, two statistical analysis approaches
were used to assign participants to cohorts. These
approaches were based on either a) the medication partici-
pants were receiving at study entry (i.e., CMS-alone or
olanzapine ± CMS); or b) the predominant treatment (PT)
the participant received during the study (i.e., PT-CMS or
PT-olanzapine). For each participant, PT was defined as
the drug with the highest cumulative number of defined
daily dose (DDD) units [43] over the course of the study.
In cases where a medication dose was missing, a value of
1 DDD unit was assigned. Where the outcome was remis-
sion, the PT period was calculated from the study entry
visit to the first remission visit. Where relapse was the
outcome, the PT period was calculated from the first
remission visit to the first relapse visit. For the purpose of
analysis, the remission visit was considered as the new
study entry for this period.
All statistical analyses were performed using SASW for
Windows, version 9.1.3 (SAS Institute, Cary, NC, USA).
Descriptive statistics were used to characterize partici-
pants at study entry for all demographic and clinical mea-
sures. Propensity scores were constructed and used in an
attempt to create balance between comparison groups
[44,45]. Variables in the propensity score model included
race, gender, income, diagnosis, age, body mass index,
recurrent major depressive episode (MDE), alcohol abuse
risk, length of hospitalization, medication adherence,
attempted suicide (in the past month), amount of time
treated with either mood stabilizers, antipsychotics, anti-
depressants, or benzodiazepines/hypnotics since the previ-
ous visit, episode(s) of mania or hypomania in the past
(based on MINI), EQ-5D and SF-36 summary scores, and
total YMRS, HAMD21, and SLICE/LIFE scores.
All adjusted proportions and Cox-regression models
were controlled for propensity score as well as several
additional prespecified covariates. The covariates assessed
at study entry were age, gender, diagnosis (BD I or SAD),
partner status (from SLICE/LIFE), employment status,
smoking status, attempted suicide in the month prior to
study entry (based on MINI), recurrent MDE (based on
MINI), alcohol abuse risk and CGI-BP total score. Other
covariates included site, hospitalized at visit, length of
hospitalization, alcohol dependence in previous year
(based on MINI), past episode(s) of mania (based on
MINI), medication adherence, and amount of time treated
with either mood stabilizers, benzodiazepines/hypnotics,
antipsychotics, or antidepressants since the previous visit.
The proportions of participants who either relapsed or
went in to remission were reported with and without
adjustment. Adjusted proportions were implemented
using generalized linear mixed effects models. Median
time to relapse after remission was calculated fromadjusted Cox regression models with bootstrapped 95%
confidence intervals (CI).
Longitudinal profiles of quality of life (as measured by
SF-36) were examined using mixed models repeated
measures. The model included the intercept and time as
random effects, with the remaining variables (listed
above as additional covariates) treated as fixed effects.
The Spatial Power covariance matrix was used to esti-
mate within-participant errors, and the Kenward-Roger
method was used to estimate denominator degrees of
freedom. In addition, the Type III sum-of-squares was
used for the least-squares means.
Results
Participant characteristics
Of a total of 499 participants screened, 48% (n = 240)
were enrolled, 26% (n = 129) were eligible, but unable to
participate or refused consent, and 26% (n = 130) did not
meet the inclusion criteria (Figure 1). Of the 239 partici-
pants who had post-study entry visits 222 (93%) com-
pleted the study.
Overall, participants in BCOS were on average 42 years
of age and first exhibited symptoms of mental illness at
age 18 (Table 1). The majority of patients met DSM-IV-
TR criteria for BD I (73.2% [175/239] vs. 26.8% [64/239]
for SAD). Clinical status at study entry was similar for
all participants, with the exception of HAMD21 scores,
which were significantly (p < 0.05) higher for participants
with SAD (Table 1). In general, participants with SAD
reported more occupational and social dysfunction at
study entry than those with BD I (Table 1).
Although the participant population as a whole exhib-
ited sub-threshold hypomanic features, 19.0% of partici-
pants were manic at study entry (YMRS score ≥15).
Approximately one-quarter (25.4%) of study participants
were suffering moderate-severe depression (HAMD21
score ≥19; [46]) when they entered the study; for 68.3%
(n = 41) of these participants, their depression had
improved to a mild or moderate state (HAMD21 score
<19; [46]) by 24 months.
Forty-four percent (n = 105) of participants were
admitted to hospital at least once during the study. Of
those hospitalized, 43.8% (n = 46) were single admis-
sions, although the median length of stay was 21 days
(range 1 to 345). For multiple admissions, 26.7% of
participants (n = 28) were admitted twice, 7.6% (n = 8)
had three admissions, 6.7% (n = 7) had four admissions,
and 5.7% (n = 6) had more than four (up to 9) admis-
sions during the study period.
Symptomatic relapse
One of the study’s objectives was to compare the
proportion of participants who experienced symptomatic
relapse to either manic or depressive states following
(100
Screened n=499 (100%)
Consented and 
enrolled n=240 
(48.1%)
Eligible, 
consented, but 
unable to 
participate n=2 
(0.4%)
Eligible, but 
unable to 
participate, or 
refused consent 
n=127 (25.5%)
Entered n=239 
(100%)
Completed 
n=222 (92.9%)
Discontinued due to:
Participant Decision1 n=9 (3.8%)
Death2 n=3 (1.3%)
Lost to follow-up 
n=5 (2.1%)
Not eligible 
n=130 (26.0%)
olanzapine ± CMS n=84 (35.1%)
CMS alone n=155 (64.9%)
Treatment 
cohorts at 
study entry
Figure 1 Participant Disposition. 1 One participant withdrew consent after the first study visit; study entry results n = 239, post-study entry
n = 238 (unless otherwise stated). 2 Two participants died due to natural causes, one from suicide.
Table 1 Participant population characteristics at study entry
Characteristic SAD BDI All
n = 64 n = 175 N = 239
Demographics
Age, mean (range), years 39.6 (20–66) 42.6 (19–79) 41.8 (18–79)
Gender, women,% 50.0% 61.1% 58.3%
Clinical status
Age at first symptoms of mental illness, median (range), years 18 (5–43) 17 (3–65) 17.5 (3–65)
CGI-BP-S overall score, mean (SD) 3.7 (1.2) 3.9 (1.4) 3.8 (1.3)
YMRS total score, median (range) 4.5 (0–39) 5.0 (0–45) 5.0 (0–45)
HAMD21 total score, mean (SD) 15.5 (8.4) 12.7 (8.5) 13.4 (8.6)*
At least 1 hospital admission; past 3 months,% 35.9% 32.0% 33.1%
Functional status
EQ-5D health state score, mean (SD) 61.6 (22.7) 68.2 (18.8) 66.4 (20.1)*
Daily smoker,% 56.3% 49.1% 51.0%
Daily alcohol consumption; past 3 months,% 4.7% 13.1% 10.9%
Alcohol dependence; past 12 months,% 14.1% 18.3% 17.2%
Unemployed,% 48.4% 22.3% 29.3%*
Employed/studying/housework,% 43.8% 68.6% 61.9%*
Have a partner,% 26.6% 46.9% 41.4%*
Considered suicide in the past month,% 75.0% 58.9% 63.2%*
Abbreviations: BD = bipolar I disorder; CGI-BP-S = Clinical Global Impressions-Bipolar Version – Severity of Illness scale (range 1–7); EQ-5D = EuroQol instrument;
HAMD21 = 21-item Hamilton Depression Rating scale; SAD = schizoaffective disorder; SD = standard deviation; YMRS = Young Mania Rating Scale. *Indicates
statistical significance (p < 0.05) for comparison of BD and SAD participants. All p values are based on Fisher’s exact test except for HAMD21 and EQ-5D scores,
which were tested using F-test analysis of variance.
Kulkarni et al. BMC Psychiatry 2012, 12:228 Page 5 of 11
http://www.biomedcentral.com/1471-244X/12/228
Kulkarni et al. BMC Psychiatry 2012, 12:228 Page 6 of 11
http://www.biomedcentral.com/1471-244X/12/228treatment with either CMS alone (n = 155), or olanza-
pine ± CMS (n = 84) (at study entry). Using this analysis
approach, there were no statistically significant differ-
ences between the treatment groups: 60.7% (n = 37)
participants met symptomatic relapse criteria in the
olanzapine ± CMS group compared with 65% (n = 76)
participants in the CMS alone group (p = 0.62). Even
after adjustment with propensity scores and preselected
covariates, there was no significant difference between
the two treatment groups (proportion of participants
[95% CI], olanzapine ± CMS versus CMS alone, 39.2%
[15.5% to 69.5%] vs 59.8% [33.3% to 81.6%]).
In order to better define the treatment groups, medi-
cation patterns (including dosage) were examined for
each participant, and their PT (based on DDD units)
was identified. The results based on these PT cohorts
were similar to those observed with the ‘prescribed at
study entry’ groups using adjusted relapse rates (propor-
tion of participants [95% CI], PT-olanzapine [n = 57]
versus PT-CMS [n = 121], 46.8% [19.1% to 76.6%] vs
56.9% [30.6% to 79.9%]; hazard ratio 0.765 [0.425 to
1.378]). The median time (calculated from the Cox
model) to relapse was 286 days (182 to 624 days) for the
PT-olanzapine cohort compared with 230 days (182 to
357 days) for the PT-CMS cohort.
Symptomatic and syndromal remission and relapse
To explore clinical outcomes more closely, we examined
symptomatic and syndromal remission and relapse (as
defined in the methods) to either depression or mania as
separate events for participants receiving either olanzapine
or CMS as the PT (Figure 2). The same analysis was
conducted on the ‘prescribed at study entry’ cohorts; the
findings were concordant with those shown in Figure 2.
By 24 months, the majority of participants in both the
PT-olanzapine (n = 57) and PT-CMS (n = 121) groups
had ever achieved both symptomatic and syndromal
remission of both mania and depression (Figure 2).
Regardless of PT, the overall symptomatic remission
rates were similar for mania and depression (74.5% vs
77.8%, respectively). Symptomatic relapse to a depressed
state was more than twice as common as relapse into a
manic state (pooled averages of 57.5% vs 27.0%, respect-
ively). Syndromal relapse (pooled averages of 8.3% and
11.5% for depression and mania, respectively) was less
frequent than symptomatic relapse. There were no
statistically significant differences observed between the
treatment cohorts.
Treatment patterns
Analysis of prescription pattern data suggests that all
BCOS participants received some form of mood stabilizer
consistently over the course of the study. Initially, parti-
cipants were most commonly prescribed an atypicalantipsychotic in combination with a CMS at study entry
(17.2%), followed by mood stabilizers (11.3%), atypical
antipsychotics/CMS/benzodiazapines (11.3%), then anti-
depressants/CMS (9.6%), although multiple combinations
of medications across classes were used (Figure 3). Irre-
spective of the study entry treatment group, polypharmacy
appeared to be the usual approach to pharmacological
treatment for BCOS participants, with multiple medica-
tions taken at each study visit (Figure 4). Participants took
a median of 5 different medications (ranging from 1 to 16)
over the course of the study. Please note that, in Figures 3
and 4, olanzapine is grouped with CMS in a broader
‘mood stabilizer’ grouping, which differs from the CMS
grouping used in other analyses.
Medication regimens taken by BCOS participants were
complex. Most participants spent a variable amount of
time on different medications; the median proportion of
time (and range) spent on medication from study entry
to 24 months was 100.0% (0% to 272.5%) for mood
stabilizers, 90.4% (0% to 330.9%) for antipsychotics, 9.0%
(0% to 200.0%) for antidepressants, and 4.5% (0% to
281.5%) for benzodiazepines/hypnotics. Treatment times
exceeding 100% are due to participants receiving more
than one medication from the same drug class. Similar
treatment durations were also observed in the first
12 months of the study (median time spent on medica-
tion [range]); 100% [0% to 263.1%] for mood stabilizers,
96.7% [0% to 359.0%] for antipsychotics, 6.1% [0% to
200.0%] for antidepressants, and 1.1% [0% to 263.7%] for
benzodiazepines/hypnotics.
Health related quality of life and other patient reported
outcomes
Despite the majority of participants experiencing mild
depressive and manic symptoms at study entry, study
participants reported considerable functional impair-
ment and comorbidities. Approximately 40% of partici-
pants were in a permanent relationship, and 63% had
considered suicide in the previous month (Table 1).
Further, about half (51%) the participants smoked daily,
11% consumed alcohol daily, with 17% of participants
meeting the criteria for alcohol dependence in the year
prior to joining the study (Table 1). Of the 41.6%
(n = 99) of participants who were employed (full or
part-time) at study entry, 29.3% (n = 29) were no longer
in paid employment by the end of the study, and 26.6%
(n = 37) of participants without paid employment at
study entry had secured full or part-time jobs by
24 months. Compared with study entry, unemployment
decreased at 24 months (from 29.3% to 23.1%), al-
though it remained higher than the Australia-wide rate
of 5.4% [47].
Overall, participants experienced some improvements
in quality of life during the course of the study. The SF-
Kulkarni et al. BMC Psychiatry 2012, 12:228 Page 7 of 11
http://www.biomedcentral.com/1471-244X/12/22836 mental health component scores improved signifi-
cantly over 24 months (from 36.8 to 41.2; p = 0.029;
Figure 5), although physical health component scores
remained consistent across the study (from 46.7 to 46.9;
p = 0.384).
Discussion
As a longitudinal, prospective, observational study, the
BCOS captured information on the course of treatment
of participants with BD I and SAD in a naturalistic
setting, and examined a broad range of study participant
outcomes over a 2-year period. One in two participants
screened for the study were not enrolled, due to a
combination of ineligibility (26%) and refusal of consent
or being unable to participate (26%); however, post-
enrollment participant retention was very high (93%).
Unlike those in more restrictive RCT settings, BCOSSymptomatic            Syndromal       
Mania
Remission
Relapse
Remission
Relapse
Pr
op
or
tio
n 
of
 p
ar
tic
ip
an
ts,
 %
Figure 2 Proportion of Participants Experiencing Symptomatic1 or Sy
are unadjusted data based on predominant treatment. Refer to Methods fo
syndromal relapse and syndromal remission for mania and depression. Gro
DDD units). PT-olanzapine refers to those participants (n = 57) in which ola
participants (n = 121) in which a CMS had the highest DDD unit value. 1Sym
score of ≤12 and HAMD21 ≤8; from a depressive state is defined as a HAM
on a YMRS total score of ≥15 after having met the criteria for symptomatic
score of ≥15 after having met the criterion for symptomatic remission (dep
DSM-IV-TR ‘A’ and ‘B’ criteria for current manic episode are no worse than m
(=3 on a 1–7 scale); from a depressive state is defined as all DSM-IV-TR ‘A’ c
(≤3 on a 1–7 scale), and no more than three ‘A’ criteria are mild (=3 on a 1
DSM-IV-TR criteria for current manic episode after having met the criteria fo
meeting DSM-IV-TR criteria for current depressive episode after having metparticipants were not excluded based on comorbidities,
and were free to use any adjunctive medications or
therapies. However, the requirement to be receiving at
least one of the pre-specified agents as a mood stabilizer
at study entry excluded patients receiving other treat-
ment regimens.
In considering the clinical correlates of BD, we found
high symptomatic remission rates for mania and depres-
sion (>74%), demonstrating that participants experienced
adequate symptom control across both poles during the
study. However, the high relapse rate for depression
(58% vs. 27% for manic relapse) suggests that maintain-
ing long-term management of depressive symptoms is
more difficult to achieve. This aligns with results from a
long-term follow up study of BD I patients, in which
patients were symptomatically ill 47% of the time, with
depressive symptoms predominating [48].     Symptomatic           Syndromal
PT-olanzapine (n=57)
PT-CMS (n=121)
Depression
Remission Remission
Relapse
Relapse
ndromal2 Remission or Relapse into Mania or Depression. These
r the definitions of symptomatic relapse, symptomatic remission,
ups were defined based on predominant treatment (PT; based on
nzapine had the highest DDD unit value. PT-CMS refers to those
ptomatic remission: from a manic state is defined as a YMRS total
D21 total score of ≤8. Symptomatic relapse: to a manic state, is based
remission (mania); to a depressed state is based on a HAMD21 total
ression). 2Syndromal remission: from a manic state is defined as all
ild (≤3 on a 1 to 7 scale), and no more than two ‘B’ criteria are mild
riteria for current major depressive episode are no worse than mild
–7 scale). Syndromal relapse: to a manic state is based on meeting
r syndromal remission (mania); to a depressed state is based on
the criteria for syndromal remission (depression).
00
0
0
27 (11.3%)
2 (0.8%)
1
(0.4%)
6
(2.5%)
41
(17.2%)
9
(3.8%)
27
(11.3%)
9
(3.8%)
16
(6.7%)
Antidepressant (AD)
Mood
Stabilizer
(MS)
Benzodiazepine
(B)
Atypical
Antipsychotic
(AA)
Other Combinations
AD + MS: 23 (9.6%)
AD + MS + other: 10 (4.2%)
MS + Typical: 6 (2.5%)
B + MS + Typical: 6 (2.5%)
B + MS: 6 (2.5%)
* Includes combinations
Figure 3 Patterns of Psychotropic Medications1 Taken at First Visit. 1 Psychotropic medications included are: atypical antipsychotics (AA),
antidepressants (AD), benzodiazepines (B), mood stabilizers (MS; olanzapine, lithium, valporate, and carbemazepine), and other (i.e.,
anticonvulsants, anticholinergics, anxiolytics, and hypnotics).
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http://www.biomedcentral.com/1471-244X/12/228A major finding from this study was the extent of
polypharmacy used in treating people with BD. The pre-
specified comparison between the symptomatic relapse
rate of participants prescribed olanzapine ± CMS or
CMS alone at study entry was confounded by the
complexity of the treatment that participants received
over time. Polypharmacy is also prevalent in other coun-
tries; a large US study of patients with BD (n = 7406),
revealed that, although 33% of patients received an ini-
tial prescription for more than one psychotropic agent,
12 months later, the polypharmacy rate among those still
receiving treatment had risen to 50% [49].N
um
be
r o
f p
ar
tic
ip
an
ts,
 n
Number of me
Figure 4 Treatment Patterns: Total Number of Psychotropic Medicatio
are: antipsychotics, antidepressants, benzodiazepines, mood stabilizers (olan
(lamotrigine), anticholinergics, anxiolytics, and hypnotics.The key finding with respect to social outcomes
and quality of life was that while unemployment rates
improved over the 24-month study period, the rate
was still higher than in the general Australian popula-
tion [50]. In addition, participants described overall
satisfaction with life and, although their mental states
improved over time, their physical health did not. It
should be noted, however, that the physical health of
this study population was quite good, with SF-36
physical health state scores within one standard devi-
ation of the norm. Examination of personal relation-
ships showed that a significant proportion of peopledications taken, n
ns1 Taken During the Study. 1 Psychotropic medications included
zapine, lithium, valporate, and carbemazepine), anticonvulsants
SF
-3
6 
Co
m
po
ne
nt
 S
co
re
, m
ea
n
Time, months
Population 
norm1
Figure 5 Mental and Physical Health Assessment at Each Visit During the 24-Month Study. Mental and Physical health were assessed
using the Short-Form Health Survey (SF-36). 1 Population norm as provided by the SF-36 organization http://www.sf-36.org/tools/SF36.shtml.
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http://www.biomedcentral.com/1471-244X/12/228in this study with BD did not have a meaningful,
close relationship.
As mentioned previously, observational studies offer
several advantages over RCTs including: a) the oppor-
tunity to study a more diverse patient population, over
longer periods of time and; b) the ability to identify risk
factors and prognostic indicators in situations in which
it would be impossible or unethical for RCTs to do so
[25,27-30]. Specific to the BCOS, strengths of this study
included high external validity, a patient centric ap-
proach, high retention rate, real world setting to assess
treatment effectiveness, and the comprehensive use of
functional and quality of life scales. Despite the strengths
of the BCOS, several limitations should be considered
when interpreting these data. First, observational studies
are not designed to establish causal relationships but
rather to examine associations; these data should be
interpreted with caution as not all comparisons were
powered a priori. Second, the participants were required
to provide consent at study entry, thus excluding many
of the most severely ill patients, although 19% of partici-
pants in this study were manic and 25.4% were suffering
severe depression (HAMD21 score ≥19; [46]). Third,
concomitant therapies such as counselling and psycho-
therapy were not captured, thus their potential impact
on outcomes could not be evaluated. Fourth, HAMD21
and YMRS scores assessed symptoms in the week prior
to the assessment visit. Given the fluctuating course of
symptoms, this week may not adequately reflect symp-
toms across the 3-month visit interval. However, the
2-year prospective observation period allowed an
extended period of observation, so that the fluctuating
course of illness and outcomes could be captured.
Finally, the lack of randomization exposes a potential for
selection bias and unmeasured confounding; attempts
were made to address potential selection bias by adjustingthe analysis for known confounding using propensity
scores, although unmeasured confounding remains a limi-
tation. For example, participants were grouped irrespective
of diagnosis; the BCOS design pre-specified approximately
equal recruitment into each of the two primary treatment
cohorts (olanzapine ± CMS and CMS alone), however,
more participants with a diagnosis of SAD were in the
olanzapine ± CMS cohort (38%) as compared with the
CMS alone cohort (22%); since the BD indication was new
for olanzapine, these participants may not reflect those
currently using this medication.
Our naturalistic data suggest that participants were
receiving diverse, complex medication treatments that led
to some overall clinical and functional improvement.
However, not all participants achieved remission of symp-
toms or syndrome. Persistent depressive symptoms were
common for this sample, with 58% of participants experi-
encing symptomatic relapse of depression at some point.
Given the complexity of treatment, we split participants
into PT cohorts to explore the comparative treatment
effectiveness but with limited success. Few differences
were observed between the treatment cohorts; the use of
multiple mood stabilizers and other concomitant medica-
tions made it difficult to attribute reported outcomes to
any one treatment group, and thus elucidate the role of
individual medications. This is an important limitation,
particularly in terms of making recommendations on
prescribing practices. It should be noted that a recent
multiple-treatment meta-analysis (data from 68 RCTs)
which ranked efficacy and acceptability of drugs used to
treat mania concluded that olanzapine was one of two
antipsychotic drugs that ranked superior in terms of
efficacy and acceptability [11,51]. An analysis of direct and
indirect costs borne by the BCOS participant population,
including healthcare resource use and lost productivity,
will be examined in a separate publication.
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The findings from the BCOS describe a complex patient
population receiving treatment regimens that were often
discordant with recommendations made in the major treat-
ment guidelines for either BD or SAD. The polypharmacy
approach used to treat many of the study participants was
associated with some improvement in clinical and func-
tional outcomes. However, this raises a series of questions
regarding the pragmatic utility of current clinical guidelines
[51]. The abundance and diversity of treatments reported
in the BCOS reflect the complexity of these disorders and
suggests that therapy should be tailored to the unique
requirements of each patient.
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